Research Study

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment
Principal Investigator 
Mark FitzGerald

Overview

Body Locations and Systems 
Asthma
ClinicalTrials.gov# 
NCT03170271
Status 
Recruiting
Study Start/End 
Jan 31, 2018 to May 10, 2019
Locations 
Diamond Health Care Centre
Name/Title 
Shelley Abercromby, Research Coordinator
Phone 
604-875-4111 ext.62500
Purpose of Study 

The purpose of this study is to investigate the safety and efficacy of a study drug, benralizumab, in comparison to placebo in patients with severe asthma that is not well controlled by their current asthma medications.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.